Ifetroban, an oral thromboxane receptor antagonist, significantly improved left ventricular ejection fraction (LVEF) in Duchenne muscular dystrophy (DMD) patients.

Tonix Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for TNX-102 SL for the treatment of fibromyalgia.

NRx Pharmaceuticals has filed the initial section of its New Drug Application (NDA) to the FDA for NRX-100 (ketamine) to treat suicidal depression.

A federal judge in Illinois ruled that Ingenus Pharmaceuticals can proceed with its patent infringement lawsuit against Nexus Pharmaceuticals regarding cyclophosphamide liquid formulations used in cancer treatment.

OliX Pharmaceuticals has received regulatory approval to commence a Phase 1 clinical trial for OLX72021, a novel treatment for androgenic alopecia, aiming to evaluate its safety and tolerability in healthy males.

NRx Pharmaceuticals' NRX-100 (Ketamine) demonstrated twelve-month real-time stability, a crucial step toward FDA approval for treating suicidal depression.

Jazz Pharmaceuticals is focusing on expanding its oncology pipeline, with key developments expected for zanidatamab and Zepzelca.

Recce Pharmaceuticals initiates a pivotal Phase 3 clinical trial in Indonesia for RECCE 327 topical gel, aimed at treating diabetic foot infections.

Kenneth Myszkowski, CFO of Arrowhead Pharmaceuticals, has sold $893,095 worth of company stock, retaining 455,433 shares. The sales, part of a pre-established trading plan, were made to cover tax obligations. Arrowhead is advancing in pharmaceutical developments and strategic partnerships, with significant clinical trials underway.

The FDA has granted Fast Track designation to Nacuity Pharmaceuticals' NPI-001 (N-acetylcysteine amide) tablets for retinitis pigmentosa (RP) treatment.

Qualigen Therapeutics is offering 14.7 million shares of common stock at $0.13 per share to fund operations and cancer drug development.

CERO Therapeutics received FDA clearance for its IND application for CER-1236, a genetically engineered human immune cell therapy, on November 15, 2024.

Moderna's stock has declined significantly from its peak, but its mRNA technology and extensive drug pipeline suggest strong potential for future growth.

Tenax Therapeutics is developing levosimendan for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), a condition affecting over 2 million U.S. patients.

Annovis Bio's Buntanetap is currently in Phase II/III clinical trials for treating mild to moderate Alzheimer's and early Parkinson's, showing potential cognitive benefits.

INmune Bio is offering 2,341,260 shares of common stock along with warrants to raise approximately $12 million for clinical trials and corporate purposes.

Kodiak Sciences' GLOW1 Phase 3 study of tarcocimab tedromer (KSI-301) in diabetic retinopathy shows a 29-fold increase in disease improvement rates.

Spectral Medical Inc. has appointed MNP LLP as its new auditor, succeeding PricewaterhouseCoopers LLP (PwC), effective immediately.

Aldeyra Therapeutics' NDA for Reproxalap in dry eye disease has a PDUFA date of November 23, 2023, with commercial preparations underway, highlighting its potential in a $23 billion market.

GeoVax is focusing on advancing its Phase 2 clinical-stage products, Gedeptin for head and neck cancer, and GEO-CM04S1, a next-generation COVID-19 vaccine.